ALKBH1:癌症治疗的新兴生物标志物和治疗标
Ming Zhu Xiao1, Jin Yin Fu1, Le Tao Bo2
1Key Laboratory of Pharmaceutical Bioactive Substances, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, China.
Discover oncology
|December 20, 2024
概括
在癌症中,AlkB同位素1 (ALKBH1) 被上调,这表明它在癌症发展中的作用. 这项研究回顾了ALKBH1的研究.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 新生细胞在增殖,传播和透过程中表现出显著的表观遗传变化.
- 甲基酶的AlkB家族,特别是AlkB同位素1 (ALKBH1),在各种恶性瘤中显著上调.
- ALKBH1的高度表达使其成为新型抗癌策略的有希望的目标.
研究的目的:
- 综合过去十年来了解ALKBH1在瘤发生中的作用的最新进展.
- 解决目前关于ALKBH1在癌症中的综合机制的知识差距.
- 为未来研究基于表观遗传的癌症预防和治疗提供基础.
主要方法:
- 关于ALKBH的最新研究的文献综述和综合1.
- 在恶性组织中分析ALKBH1表达模式.
- 关于将ALKBH1与瘤发生联系起来的拟议机制的审查.
主要成果:
- 在一系列癌症中,ALKBH1的表达一直过度.
- 有证据表明,ALKBH1在癌症发展的各个阶段起着重要作用.
- 最近的研究已经开始阐明涉及ALKBH1在瘤发生过程中的特定分子途径.
结论:
- ALKBH1是一个关键的表观遗传调节器,与癌症有关.
- 对ALKBH1机制的进一步研究可能会导致向癌症治疗.
- 利用表观遗传修饰为未来的癌症预防和治疗提供了一个有希望的途径.
更多相关视频
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
16.5K
09:59Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
Published on: March 31, 2023
1.0K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
